doctor with elderly man

Consensus guideline on the holistic management of patients requiring anticoagulation

2020-06-03T06:57:00+01:00By Working party–Fay Antoniou Martins Merriman Patrickson Uprichard

This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.

Pad+stethoscope 640x426

Stable peripheral arterial disease guideline

2018-12-07T15:50:00+00:00By Working party—Begg Antoniou Fay Garnham Nuttall

This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.

Pregnant women with GP AS

Stable coronary artery disease guideline

2018-12-04T12:08:00+00:00By Working party­—Fay Banerjee Begg Bostock-Cox Gordon

This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.

Erythrocytes tinted SIGN Red

SIGN antithrombotics guideline

2014-11-06T00:00:00+00:00By

A clear SIGN guideline summary exploring antiplatelet and anticoagulant agents and indications for their use, including cardiac and cerebrovascular disease.

Resource hub

  • Practical guide to recording ankle brachial pressure index (ABPI)

Educational resources

G4P pharmacist counselling checklist

Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information

PP-XAR-GB-2051  April 2021

GLNs prescribers checklist_DVT and PE

Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for eligible patients with DVT or PE*

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for treatment of DVT and  PE, and prevention of recurrent DVT and PE in adults.

PP-XAR-GB-2053  April 2021

GLNs prescribers checklist_SPAF

Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

PP-XAR-GB-2052  April 2021

Video index image

The holistic management of patients requiring anticoagulation

Commissioned by Bayer plc

This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines
View Xarelto(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021

VTE webinar index image

Modern management of venous thromboembolism in primary care

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS − Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View Eliquis (apixaban) prescribing and adverse event reporting information
432-GB-2100016        
Date of preparation: February 2021